Banque Cantonale Vaudoise lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 9.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,193 shares of the company’s stock after selling 2,882 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Elanco Animal Health were worth $247,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Ethic Inc. boosted its position in Elanco Animal Health by 73.4% during the third quarter. Ethic Inc. now owns 26,192 shares of the company’s stock valued at $325,000 after purchasing an additional 11,088 shares in the last quarter. Trexquant Investment LP boosted its position in Elanco Animal Health by 109.5% during the third quarter. Trexquant Investment LP now owns 210,226 shares of the company’s stock valued at $2,609,000 after purchasing an additional 109,881 shares in the last quarter. ING Groep NV acquired a new stake in Elanco Animal Health in the fourth quarter worth about $7,332,000. Geneos Wealth Management Inc. boosted its holdings in Elanco Animal Health by 33.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 28,307 shares of the company’s stock worth $346,000 after acquiring an additional 7,154 shares in the last quarter. Finally, Transcend Capital Advisors LLC boosted its holdings in Elanco Animal Health by 10.6% in the fourth quarter. Transcend Capital Advisors LLC now owns 11,534 shares of the company’s stock worth $141,000 after acquiring an additional 1,106 shares in the last quarter. Institutional investors own 94.81% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, Barclays raised Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price target for the company in a report on Thursday, April 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $15.40.
Elanco Animal Health Trading Down 1.3 %
Elanco Animal Health (NYSE:ELAN – Free Report) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.16. Elanco Animal Health had a positive return on equity of 8.21% and a negative net margin of 0.49%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the business posted $0.36 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities analysts predict that Elanco Animal Health Incorporated will post 0.8 EPS for the current year.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Articles
- Five stocks we like better than Elanco Animal Health
- 3 Russell 2000 Stocks to Buy as Small-Caps Make a Comeback
- These Banks Are Boosting Dividends After Safe Stress Tests
- Three (3) Stocks Under $10 That Insiders Are BuyingÂ
- 3 Cash-Rich Defensive Companies Making Investors Rich
- Can Valero Energy Corporation Rise To New Highs In 2023?
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
